TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
Brief Summary: This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks). Planned duration of double-blind treatment is 96 weeks. Participants who complete the 96-week double-blind treatment will have an option to enter a single-group, active-treatment, open-label extension period, providing they fulfill the eligibility criteria.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1: lipoic acid; Type: EXPERIMENTAL; Interventions: Drug: lipoic acid | Arm Label: Arm 2: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lipoic acid; Assigned to Arm(s): Arm 1: lipoic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2: placebo
C: Arm Label: with Multiple Sclerosis/ vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A | Arm Label: with Multiple Sclerosis/ placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): with Multiple Sclerosis/ vitamin A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): with Multiple Sclerosis/ placebo
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
Brief Summary: This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks). Planned duration of double-blind treatment is 96 weeks. Participants who complete the 96-week double-blind treatment will have an option to enter a single-group, active-treatment, open-label extension period, providing they fulfill the eligibility criteria.


Options:
A: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
B: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Monocenter Randomized Clinical Trial of PAClitaxel drUg-eluting BAlloon Versus Standard Percutaneous Transluminal Angioplasty to Reduce Restenosis in Patients With In-stent Stenoses in the Superficial Femoral and Proximal Popliteal Artery
Brief Summary: Prospective monocenter single-blind randomized (1:1) investigator sponsored clinical trial, in which consecutive patients candidates for percutaneous intervention of angioplasty to treat symptomatic in-stent restenosis of the SFA and P1 segment of the popliteal artery will be assigned to one of two study arms:

1. Treatment Arm: Paclitaxel eluting percutaneous transluminal angioplasty (PePTA)
2. Control Arm: standard percutaneous transluminal angioplasty (sPTA).

Purpose:

To evaluate the morphologic and clinical efficacy of Paclitaxel eluting percutaneous transluminal angioplasty (PePTA) for the reduction of restenosis in SFA and PA stents compared to standard percutaneous transluminal angioplasty (sPTA).


Options:
A: Arm Label: Paclitaxel eluting balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting balloon angioplasty | Arm Label: Standard balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: standard balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting balloon angioplasty; Assigned to Arm(s): Paclitaxel eluting balloon | Intervention Type: DEVICE; Name: standard balloon angioplasty; Assigned to Arm(s): Standard balloon angioplasty
B: Arm Label: Standart balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Admiral Xtreme | Arm Label: Paclitaxel-eluting balloon arm; Type: ACTIVE_COMPARATOR; Interventions: Device: In.Pact Admiral | Intervention Type: DEVICE; Name: Admiral Xtreme; Assigned to Arm(s): Standart balloon angioplasty | Intervention Type: DEVICE; Name: In.Pact Admiral; Assigned to Arm(s): Paclitaxel-eluting balloon arm
C: Arm Label: Endoprosthesis; Type: EXPERIMENTAL; Interventions: Device: GORE VIABAHN® Endoprosthesis | Arm Label: Plain old balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Plain old balloon angioplasty | Intervention Type: DEVICE; Name: GORE VIABAHN® Endoprosthesis; Assigned to Arm(s): Endoprosthesis | Intervention Type: DEVICE; Name: Plain old balloon angioplasty; Assigned to Arm(s): Plain old balloon angioplasty
D: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma
Brief Summary: The purpose of the study is to find out if taking vitamin D in addition to an asthma controller medication helps to prevent worsening of asthma symptoms and asthma attacks.


Options:
A: Arm Label: Vitamin D3 100,000 IU; Type: EXPERIMENTAL; Interventions: Drug: Experimental: Vitamin D3 100,000 IU | Arm Label: Vitamin D3 12,000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator: Vitamin D3 12,000 IU | Intervention Type: DRUG; Name: Experimental: Vitamin D3 100,000 IU; Assigned to Arm(s): Vitamin D3 100,000 IU | Intervention Type: DRUG; Name: Active Comparator: Vitamin D3 12,000 IU; Assigned to Arm(s): Vitamin D3 12,000 IU
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
D: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma
Brief Summary: The purpose of the study is to find out if taking vitamin D in addition to an asthma controller medication helps to prevent worsening of asthma symptoms and asthma attacks.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: daily vitamin D supplement, Other: Placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: daily vitamin D supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: daily vitamin D supplement; Assigned to Arm(s): Placebo, Vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
D: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Nitroprusside on the IUD Insertion Experience in Nulliparous Women: a Pilot Study
Brief Summary: Increasing accessibility of long-acting reversible contraceptive methods, like intrauterine devices (IUDs), is an important strategy to reduce the risk of unintended pregnancy. Unfortunately, fear of IUD insertion in women who have not had children is common among health care providers and women alike, and this limits IUD use. To increase acceptance of this highly effective contraceptive, there is need to investigate novel, low cost, easily applied and accessible techniques to improve the insertion experience. This is a pilot study to evaluate the efficacy and tolerability of nitroprusside gel applied intracervically as an intervention to improve the IUD insertion experience for both patient and provider.


Options:
A: Arm Label: Oxygen (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Oxygen | Arm Label: Nitrous Oxide (NO); Type: EXPERIMENTAL; Interventions: Procedure: IUD insertion, Drug: Povidone-Iodine, Drug: Chlorhexidine, Other: Nitrous oxide | Intervention Type: PROCEDURE; Name: IUD insertion; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Povidone-Iodine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): Nitrous Oxide (NO), Oxygen (Placebo) | Intervention Type: OTHER; Name: Oxygen; Assigned to Arm(s): Oxygen (Placebo) | Intervention Type: OTHER; Name: Nitrous oxide; Assigned to Arm(s): Nitrous Oxide (NO)
B: Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo Gel | Arm Label: Nitroprusside Gel; Type: EXPERIMENTAL; Interventions: Procedure: Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Nitroprusside Gel; Assigned to Arm(s): Nitroprusside Gel | Intervention Type: PROCEDURE; Name: Placebo Gel; Assigned to Arm(s): Placebo gel
C: Arm Label: Group 1: Intravaginal 2% lidocaine gel; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Arm Label: Group 2: Intravaginal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 1: Intravaginal 2% lidocaine gel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Intravaginal placebo gel
D: Arm Label: lidocaine gel; Type: EXPERIMENTAL; Interventions: Drug: 2% lidocaine gel | Arm Label: placebo gel (surgilube); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: 2% lidocaine gel; Assigned to Arm(s): lidocaine gel | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo gel (surgilube)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Brief Summary: A randomized, controlled clinical trial to assess whether text messaging to an outpatient obstetric population can improve maternal influenza vaccine uptake.


Options:
A: Arm Label: Lay Health Worker Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lay Health Worker Intervention | Arm Label: Placebo (a list of resources); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo (a list of resources) | Intervention Type: BEHAVIORAL; Name: Lay Health Worker Intervention; Assigned to Arm(s): Lay Health Worker Intervention | Intervention Type: BEHAVIORAL; Name: Placebo (a list of resources); Assigned to Arm(s): Placebo (a list of resources)
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Parent Only Group; Type: EXPERIMENTAL; Interventions: Other: Parent Only Phone Call | Arm Label: Parent and Adolescent Group; Type: EXPERIMENTAL; Interventions: Other: Parent and Adolescent Phone Call | Intervention Type: OTHER; Name: Parent Only Phone Call; Assigned to Arm(s): Parent Only Group | Intervention Type: OTHER; Name: Parent and Adolescent Phone Call; Assigned to Arm(s): Parent and Adolescent Group
C: Arm Label: General health information; Type: PLACEBO_COMPARATOR; Interventions: Other: general health information | Arm Label: Influenza and general health information; Type: ACTIVE_COMPARATOR; Interventions: Other: influenza and general health information | Intervention Type: OTHER; Name: influenza and general health information; Assigned to Arm(s): Influenza and general health information | Intervention Type: OTHER; Name: general health information; Assigned to Arm(s): General health information
D: Arm Label: Outreach; Type: OTHER; Interventions: Other: outreach services | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: outreach services; Assigned to Arm(s): Outreach

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Brief Summary: A randomized, controlled clinical trial to assess whether text messaging to an outpatient obstetric population can improve maternal influenza vaccine uptake.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
B: Arm Label: cMM and Text Messaging; Type: OTHER; Interventions: Behavioral: cMM, Behavioral: Text Messaging | Arm Label: cMM Only; Type: OTHER; Interventions: Behavioral: cMM | Arm Label: Text Messaging Only; Type: OTHER; Interventions: Behavioral: Text Messaging | Arm Label: Neither cMM nor Text Messaging; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: cMM; Assigned to Arm(s): cMM Only, cMM and Text Messaging | Intervention Type: BEHAVIORAL; Name: Text Messaging; Assigned to Arm(s): Text Messaging Only, cMM and Text Messaging
C: Arm Label: General health information; Type: PLACEBO_COMPARATOR; Interventions: Other: general health information | Arm Label: Influenza and general health information; Type: ACTIVE_COMPARATOR; Interventions: Other: influenza and general health information | Intervention Type: OTHER; Name: influenza and general health information; Assigned to Arm(s): Influenza and general health information | Intervention Type: OTHER; Name: general health information; Assigned to Arm(s): General health information
D: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Brief Summary: A randomized, controlled clinical trial to assess whether text messaging to an outpatient obstetric population can improve maternal influenza vaccine uptake.


Options:
A: Arm Label: General health information; Type: PLACEBO_COMPARATOR; Interventions: Other: general health information | Arm Label: Influenza and general health information; Type: ACTIVE_COMPARATOR; Interventions: Other: influenza and general health information | Intervention Type: OTHER; Name: influenza and general health information; Assigned to Arm(s): Influenza and general health information | Intervention Type: OTHER; Name: general health information; Assigned to Arm(s): General health information
B: Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling delivered by telephone; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Telephone Support Intervention to Improve Breastfeeding | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone Support Intervention to Improve Breastfeeding; Assigned to Arm(s): A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake
Brief Summary: A randomized, controlled clinical trial to assess whether text messaging to an outpatient obstetric population can improve maternal influenza vaccine uptake.


Options:
A: Arm Label: General health information; Type: PLACEBO_COMPARATOR; Interventions: Other: general health information | Arm Label: Influenza and general health information; Type: ACTIVE_COMPARATOR; Interventions: Other: influenza and general health information | Intervention Type: OTHER; Name: influenza and general health information; Assigned to Arm(s): Influenza and general health information | Intervention Type: OTHER; Name: general health information; Assigned to Arm(s): General health information
B: Arm Label: Usual care / opportunistic screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Letter and informational sheet; Type: EXPERIMENTAL; Interventions: Other: Letter and informational sheet | Arm Label: Email; Type: EXPERIMENTAL; Interventions: Other: Email | Arm Label: Phone; Type: EXPERIMENTAL; Interventions: Other: Phone | Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Other: Multimodal | Intervention Type: OTHER; Name: Letter and informational sheet; Assigned to Arm(s): Letter and informational sheet | Intervention Type: OTHER; Name: Email; Assigned to Arm(s): Email | Intervention Type: OTHER; Name: Phone; Assigned to Arm(s): Phone | Intervention Type: OTHER; Name: Multimodal; Assigned to Arm(s): Multimodal
C: Arm Label: Two-way SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Two-way SMS | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Two-way SMS; Assigned to Arm(s): Two-way SMS
D: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention

Answer: A